Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less. A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into...
Saved in:
| Published in | Iranian journal of public health Vol. 44; no. 11; pp. 1466 - 1472 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Iran
Tehran University of Medical Sciences
01.11.2015
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2251-6085 2251-6093 |
Cover
Loading…
| Abstract | We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less.
A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml. The reliability of cancer detection in relation to the f/t PSA ratio and PSAD were estimated.
Overall, 65 people were diagnosed with prostate cancer. The detection rate was 16.28%、17.17%, 21.82%, 25.00% in subjects with PSA levels of 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml, respectively. The f/t PSA ratio was significantly lower in patients with prostate cancer and PSA levels of 2.1 to 4.0 ng/ml (P<0.05). The PSAD had no statistical significance between the two groups.
Routine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with /without abnormal DRE/TRUS findings. |
|---|---|
| AbstractList | We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less.
A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml. The reliability of cancer detection in relation to the f/t PSA ratio and PSAD were estimated.
Overall, 65 people were diagnosed with prostate cancer. The detection rate was 16.28%、17.17%, 21.82%, 25.00% in subjects with PSA levels of 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml, respectively. The f/t PSA ratio was significantly lower in patients with prostate cancer and PSA levels of 2.1 to 4.0 ng/ml (P<0.05). The PSAD had no statistical significance between the two groups.
Routine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with /without abnormal DRE/TRUS findings. We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less. A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml. The reliability of cancer detection in relation to the f/t PSA ratio and PSAD were estimated. Overall, 65 people were diagnosed with prostate cancer. The detection rate was 16.28%, 17.17%, 21.82%, 25.00% in subjects with PSA levels of 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml, respectively. The f/t PSA ratio was significantly lower in patients with prostate cancer and PSA levels of 2.1 to 4.0 ng/ml (P<0.05). The PSAD had no statistical significance between the two groups. Routine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with /without abnormal DRE/TRUS findings. We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less.BACKGROUNDWe aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less.A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml. The reliability of cancer detection in relation to the f/t PSA ratio and PSAD were estimated.METHODSA total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml. The reliability of cancer detection in relation to the f/t PSA ratio and PSAD were estimated.Overall, 65 people were diagnosed with prostate cancer. The detection rate was 16.28%、17.17%, 21.82%, 25.00% in subjects with PSA levels of 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml, respectively. The f/t PSA ratio was significantly lower in patients with prostate cancer and PSA levels of 2.1 to 4.0 ng/ml (P<0.05). The PSAD had no statistical significance between the two groups.RESULTSOverall, 65 people were diagnosed with prostate cancer. The detection rate was 16.28%、17.17%, 21.82%, 25.00% in subjects with PSA levels of 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml, respectively. The f/t PSA ratio was significantly lower in patients with prostate cancer and PSA levels of 2.1 to 4.0 ng/ml (P<0.05). The PSAD had no statistical significance between the two groups.Routine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with /without abnormal DRE/TRUS findings.CONCLUSIONSRoutine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with /without abnormal DRE/TRUS findings. Background: We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less. Methods: A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml. The reliability of cancer detection in relation to the f/t PSA ratio and PSAD were estimated. Results: Overall, 65 people were diagnosed with prostate cancer. The detection rate was 16.28%、17.17%, 21.82%, 25.00% in subjects with PSA levels of 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, 2.1 to 3.0 ng/ml, and 3.1 to 4.0 ng/ml, respectively. The f/t PSA ratio was significantly lower in patients with prostate cancer and PSA levels of 2.1 to 4.0 ng/ml (P＜0.05). The PSAD had no statistical significance between the two groups. Conclusions: Routine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with /without abnormal DRE/TRUS findings. Keywords: Biopsy, Prostate cancer, Prostate-specific antigen, PSA ratio, PSAD |
| Author | Li, Qiu-Yang Liu, Xin Fei, Xiang Tang, Jie |
| Author_xml | – sequence: 1 givenname: Xin surname: Liu fullname: Liu, Xin organization: Ultrasonography Department of Nan Lou Clinical Medicine Division, Chinese PLA General Hospital, China – sequence: 2 givenname: Jie surname: Tang fullname: Tang, Jie organization: Dept. of Ultrasonography, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, China – sequence: 3 givenname: Xiang surname: Fei fullname: Fei, Xiang organization: Dept. of Ultrasonography, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, China – sequence: 4 givenname: Qiu-Yang surname: Li fullname: Li, Qiu-Yang organization: Dept. of Ultrasonography, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26744703$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkt1q3DAQhU1IyV_7CkXQm-TCrWTJlnRTWDZNGlhoaNJrIUtjR4tX2kralLxLHjbK39LkaoYzh28GHR1Wuz542KkOmqYldYcl3d32ot2vDlNaYsy6puV71X7TccY4pgfV_WUMKesMdVqDcYMzaOazG8Gj48ur2Qk6BZ9cvkPaW3QWAVAO6DpkPaEyRr91dgE5j06dHn1Izo_olYjm2huI6J_LN1uxvnq_ZgG3MCUUBsS-YuTHb6sJhVjklD5WHwY9Jfj0Uo-qP2c_ruc_68Wv84v5bFFb2uFcg257jTUX3Ao-UIxt1w4DM6JnBpvGtkT2wNpGYEZb23HS9dZIbiXRsusA6FF18cy1QS_VOrqVjncqaKeehBBHpWN2ZgLFBB5gsKzvpWWPC4mQDaGs4DmRhBTW92fWetOvwBrwOerpDfTtxLsbNYZb9ZhHCawAjl8AMfzdQMpq5ZKBadIewiYpwkuiQhDKi_XLO-sybKIvT1VcVHCJG4qL6_P_F21Pef0E9AF9R6-x |
| ContentType | Journal Article |
| Copyright | Copyright Dr Ali Akbari Sari, Director of The Commission for Accreditation & Improvement of Iranian Medical Journals Nov 2015 Copyright© Iranian Public Health Association & Tehran University of Medical Sciences 2015 |
| Copyright_xml | – notice: Copyright Dr Ali Akbari Sari, Director of The Commission for Accreditation & Improvement of Iranian Medical Journals Nov 2015 – notice: Copyright© Iranian Public Health Association & Tehran University of Medical Sciences 2015 |
| DBID | NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA ATCPS AZQEC BENPR BHPHI CCPQU CWDGH DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S PATMY PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PYCSY 7X8 5PM DOA |
| DatabaseName | PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database (ProQuest) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Natural Science Collection ProQuest One Community College Middle East & Africa Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Sustainability Health Research Premium Collection Middle East & Africa Database Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed ProQuest Central Student MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 2251-6093 |
| EndPage | 1472 |
| ExternalDocumentID | oai_doaj_org_article_480fefd4bb9d487d8189213445271911 PMC4703225 3883274961 26744703 |
| Genre | Journal Article Feature |
| GroupedDBID | 04C 29J 2NT 2WC 44B 53G 5GY 5VS 7X7 7XC 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AAWTL ABUWG ACHQT ADBBV ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ATCPS BAWUL BENPR BHPHI BMSDO BPHCQ BVXVI CCPQU CWDGH C~G DIK DYU E3Z EIHBH F5P FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE KQ8 M48 NPM OK1 OVT P2P PATMY PGMZT PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PYCSY Q2X RNS RPM TR2 UKHRP 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-d360t-ea5ba0a787d87f300d65ff4c8b4c0c2d519be45280435d6716bdc97d91a966ee3 |
| IEDL.DBID | BENPR |
| ISSN | 2251-6085 |
| IngestDate | Wed Aug 27 01:32:47 EDT 2025 Thu Aug 21 18:25:48 EDT 2025 Thu Sep 04 19:11:43 EDT 2025 Fri Jul 25 03:23:30 EDT 2025 Mon Jul 21 05:57:36 EDT 2025 |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | PSA ratio PSAD Biopsy Prostate-specific antigen Prostate cancer |
| Language | English |
| License | This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d360t-ea5ba0a787d87f300d65ff4c8b4c0c2d519be45280435d6716bdc97d91a966ee3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/480fefd4bb9d487d8189213445271911 |
| PMID | 26744703 |
| PQID | 1738790230 |
| PQPubID | 105761 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_480fefd4bb9d487d8189213445271911 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4703225 proquest_miscellaneous_1760888137 proquest_journals_1738790230 pubmed_primary_26744703 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-Nov 20151101 2015-11-01 |
| PublicationDateYYYYMMDD | 2015-11-01 |
| PublicationDate_xml | – month: 11 year: 2015 text: 2015-Nov |
| PublicationDecade | 2010 |
| PublicationPlace | Iran |
| PublicationPlace_xml | – name: Iran – name: Tehran |
| PublicationTitle | Iranian journal of public health |
| PublicationTitleAlternate | Iran J Public Health |
| PublicationYear | 2015 |
| Publisher | Tehran University of Medical Sciences |
| Publisher_xml | – name: Tehran University of Medical Sciences |
| References | 15163773 - N Engl J Med. 2004 May 27;350(22):2239-46 10443714 - Urology. 1999 Aug;54(2):220-4 1692885 - J Urol. 1990 Jun;143(6):1146-52; discussion 1152-4 12878740 - N Engl J Med. 2003 Jul 24;349(4):335-42 20660846 - Arch Intern Med. 2010 Jul 26;170(14):1256-61 7525995 - J Urol. 1994 Dec;152(6 Pt 1):2037-42 16140074 - Urology. 2005 Sep;66(3):542-6 19297565 - N Engl J Med. 2009 Mar 26;360(13):1310-9 7512659 - J Urol. 1994 May;151(5):1283-90 9730459 - Urology. 1998 Sep;52(3):450-4 15667646 - BJU Int. 2005 Feb;95(2):231-7 10022696 - J Urol. 1999 Mar;161(3):835-9 8567109 - Int J Cancer. 1996 Jan 17;65(2):145-51 10799172 - J Urol. 2000 Jun;163(6):1739-42 4989232 - J Reprod Fertil. 1970 Aug;22(3):573-4 9145717 - JAMA. 1997 May 14;277(18):1452-5 11744475 - Urology. 2001 Dec;58(6):994-8 11340290 - Eur Urol. 2001 Apr;39 Suppl 4:43-6 19278718 - Urology. 2009 May;73(5):1098-103 19297566 - N Engl J Med. 2009 Mar 26;360(13):1320-8 |
| References_xml | – reference: 15667646 - BJU Int. 2005 Feb;95(2):231-7 – reference: 10799172 - J Urol. 2000 Jun;163(6):1739-42 – reference: 19297565 - N Engl J Med. 2009 Mar 26;360(13):1310-9 – reference: 10022696 - J Urol. 1999 Mar;161(3):835-9 – reference: 1692885 - J Urol. 1990 Jun;143(6):1146-52; discussion 1152-4 – reference: 7512659 - J Urol. 1994 May;151(5):1283-90 – reference: 8567109 - Int J Cancer. 1996 Jan 17;65(2):145-51 – reference: 19297566 - N Engl J Med. 2009 Mar 26;360(13):1320-8 – reference: 11340290 - Eur Urol. 2001 Apr;39 Suppl 4:43-6 – reference: 7525995 - J Urol. 1994 Dec;152(6 Pt 1):2037-42 – reference: 10443714 - Urology. 1999 Aug;54(2):220-4 – reference: 19278718 - Urology. 2009 May;73(5):1098-103 – reference: 20660846 - Arch Intern Med. 2010 Jul 26;170(14):1256-61 – reference: 9730459 - Urology. 1998 Sep;52(3):450-4 – reference: 12878740 - N Engl J Med. 2003 Jul 24;349(4):335-42 – reference: 11744475 - Urology. 2001 Dec;58(6):994-8 – reference: 16140074 - Urology. 2005 Sep;66(3):542-6 – reference: 15163773 - N Engl J Med. 2004 May 27;350(22):2239-46 – reference: 9145717 - JAMA. 1997 May 14;277(18):1452-5 – reference: 4989232 - J Reprod Fertil. 1970 Aug;22(3):573-4 |
| SSID | ssj0046257 |
| Score | 1.9745207 |
| Snippet | We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients... Background: We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the... |
| SourceID | doaj pubmedcentral proquest pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1466 |
| SubjectTerms | Age Antigens Confidence intervals Original Prostate cancer |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT0gI8SalVIPEAQ6mTuJHcty2rCqEUEVbqbfIjm2oBE61mx74L_xYZuLdVbdC4sLVzsOZb-z5xpkZM_ZW9dK0vi-5kjJwXPAUt43zvJJK9kggnPFTgOwXfXIhP12qy1tHfVFMWC4PnAV3IBsRQ_TSudYjufZoYFqqQiZVZdDXmBwftHlrZyqvwVLnGp-orCXXgg5Kniry_41G3o2GvGVe5o_YwxUvhFkez2N2L6Qn7EHeVIOcK_SU_T6lHA1kh5wSJCnIB2ZppHqa8O70bPYejikcffwFNnmYL0KAcYDzAfk1YDd8JRTgKsFxjq9DqwXrJ8IRwb8A2pfdNPKzu6_5TDFGSxgiyA8C0reDnz9gWGDzcvmMXcw_nh-d8NXxCtzXWow8WOWssIaEamIthNcqRtk3TvairzxyOxdQzI1ASuU1OlbO9y1iV1r0kUKon7OdNKTwkoFDHqKdjnXUQlpdtaEyPtq-CUaV2seCHZL4u-tcQaOjmtZTAyLdrZDu_oV0wfbW4HWribbsSlM3piVHqmBvNt04Rei_h01huKFrUAWapqxNwV5krDcjqbSREle9gpktLdga6nZPuvo-leGm21DBdv_Ht71i95GJqZzkuMd2xsVNeI1sZ3T7k2L_AWNL_is priority: 102 providerName: Directory of Open Access Journals |
| Title | Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26744703 https://www.proquest.com/docview/1738790230 https://www.proquest.com/docview/1760888137 https://pubmed.ncbi.nlm.nih.gov/PMC4703225 https://doaj.org/article/480fefd4bb9d487d8189213445271911 |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF7R9IKEKt4YSjRIHOCw1I99-YTStFGFoIraRgony-tdl0pgt7F74L_wY5mxnUAqxGUPu36MPA9_OzsPxt7KQujUFRGXQniOBk_y3FjHYyFFgQDCatcFyJ6qk4X4tJTLweHWDGGVa5vYGWpXF-QjP4h0YnRKiPnj9Q2nrlF0ujq00Nhhu2iCjRyx3cPj0_nZ2hYL1df6RKGNuAqpYXJXmf9fcPJuVORfv5nZQ7Y34EOY9Ax9xO756jF70DvXoM8ZesJ-zSlXA1Eip0RJCvaBSdVSXU14Nz-fvIcjCktvf0JeOZitvIe2hosacTbgMpwRN-CqgqM-zg7_XrB-IkxJDFZA_tnNJD-_-5rPFGvUQF2C-BBCdXnw4zvUK5xumqdsMTu-mJ7woc0Cd4kKW-5zafMwR811RpdJGDoly1IUxooiLGKHGM96IWMTIrRyCjdY1hUp8jDKca_kffKMjaq68i8YWMQjyqoyKVUochWnPtauzAvjtYyUKwN2SJ8_u-4raWRU27qbqFeX2aAqmTBh6UsnrE2dIKIik1LdOSRB4-4yCtj-mnnZoHBN9kc8AvZms4yqQucfeeXrW7oGRcCYKNEBe97zekNJrLQQaP0CprekYIvU7ZXq6ltXjptuQwF7-X-yXrH7iLVkn8a4z0bt6ta_RjzT2jHb0UuNo5lG40GAx51vgMavCxy_CPMbXZP87g |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKewAJId4ECgwSSHBwm4djJweEtt2utnRZrdqt1FuIY6dUgqRsUqH-F34Dv5GZPBa2Qtx6tfMYZb6ZfLbnwdjrMBMqNpnHQyEsR4cX8jTShvsiFBkSCK1MEyA7leNj8fEkPFljv_pcGAqr7H1i46hNmdEe-bangkjFxJg_nH_n1DWKTlf7FhotLA7s5Q9cslXv94eo3ze-P9qb745511WAm0C6NbdpqFM3RaCaSOWB6xoZ5rnIIi0yN_MNUhptRehHLjIJI3E9oU0Wo8heiksDawN87g22gZMxWtHGzt50dtj7fiHb2qJoJB6XLjVobjoB_Iu-Xo3C_Ou3NrrL7nR8FAYtgO6xNVvcZ7fbzTxoc5QesJ8zyg1BVsopMZOCi2BQ1FTHE97OjgbvYEhh8PUlpIWB0cJaqEuYl8jrAafhkLQPZwUM27g-_FtC_0TYJdgtgPaDl4P86OprJhTbVEGZg9hyoTjd_vYVygUOV9VDdnwtCnjE1ouysE8YaOQ_Uss8yKUrUunH1lcmT7PIqtCTJnfYDn3-5Lyt3JFQLe1moFycJp1pJiJyc5sboXVsBAnlRTHVuUMRFK5mPYdt9spLOgOvkj9wdNir5TSaJp23pIUtL-gahEAUeYFy2ONW10tJfKmEQG_rMLWCghVRV2eKsy9N-W-6DQH29P9ivWQ3x_NPk2SyPz14xm4hzwvbFMpNtl4vLuxz5FK1ftEBGNjn67aZ3_udNZA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyEkhLhTGHCQQIIH01wc23lAqFtXbWyqql2kvYU4tsckSEabCe2_8Ev4dZzTJIVOiLe92olzlPMd-7N9Loy9TgqhUluEPBHCcZzwEp5rY3kkElEggTDKLhxkJ3LnWHw6SU7W2K8uFobcKrs5cTFR26qgM_JBqGKtUmLMA9-6RUxH44_n3zlVkKKb1q6cRgORPXf5A7dv8w-7I9T1mygabx9t7fC2wgC3sQxq7vLE5EGOoLVa-TgIrEy8F4U2ogiKyCK9MU4kkQ6QVViJewtjixTFD3PcJjgX47g32LrCVVH32Prm9mR60K0DQjZ5RtFgQi4DKta8qArwLyp71SPzryVufJfdabkpDBsw3WNrrrzPbjcHe9DEKz1gP6cUJ4IMlVOQJjkawbCsKacnvJ0eDt_BiFzi60vISwvjmXNQV3BUIccH7IYDQgKclTBqfPxw5YRuRNgiCM6AzoaXjfzw6mf2yc9pDpUH8T6A8nTw7StUM2yezx-y42tRwCPWK6vSPWFgkAtJI33sZSByGaUuUtbnhXYqCaX1fbZJvz87b7J4ZJRXe9FQzU6z1kwzoQPvvBXGpFaQUKFOKecdiqBwZxv22UanvKw19nn2B5p99mrZjWZKdy956aoLegYhoHUYqz573Oh6KUkklRA48_aZWkHBiqirPeXZl0UqcHoNAfb0_2K9ZDfRVrL93cneM3YLKV_SRFNusF49u3DPkVbV5kWLX2Cfr9tkfgP1gTm8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostate-specific+Antigen+%28PSA%29+Density+and+Free+to+Total+PSA+Ratio+in+Diagnosing+Prostate+Cancer+with+Prostate-Specific+Antigen+Levels+of+4.0+ng%2Fml+or+Less&rft.jtitle=Iranian+journal+of+public+health&rft.au=Liu%2C+Xin&rft.au=Tang%2C+Jie&rft.au=Fei%2C+Xiang&rft.au=Li%2C+Qiu-Yang&rft.date=2015-11-01&rft.issn=2251-6085&rft.volume=44&rft.issue=11&rft.spage=1466&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2251-6085&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2251-6085&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2251-6085&client=summon |